April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Response and dependence to the induction therapy of intravitreal aflibercept in AMD
Author Affiliations & Notes
  • Noriko Miyamoto
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Dept of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Michiko Mandai
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan
  • Masataka Shimozono
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Dept of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Takanori Kameda
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Dept of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Akihiro Nishida
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Dept of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Yasuo Kurimoto
    Dept of Ophthalmology, Kobe City Med Ctr Gen Hosp, Kobe, Japan
    Dept of Ophthalmology, Institute of Biomedical Research and Innovation Hospital, Kobe, Japan
  • Footnotes
    Commercial Relationships Noriko Miyamoto, None; Michiko Mandai, None; Masataka Shimozono, None; Takanori Kameda, None; Akihiro Nishida, None; Yasuo Kurimoto, Bayer Yakuhin Ltd. (R), Novartis Pharma K.K. (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3835. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Noriko Miyamoto, Michiko Mandai, Masataka Shimozono, Takanori Kameda, Akihiro Nishida, Yasuo Kurimoto; Response and dependence to the induction therapy of intravitreal aflibercept in AMD. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3835.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We reported previously that of all treatment-naïve age-related macular degeneration (AMD) patients, 59% well-responded to ranibizumab induction therapy by achieving complete resolution of the fluid. Half of these eyes were ranibizumab-dependent requiring repeated injections and showed poorer visual outcome (2013 ARVO). In the present study, we evaluated the response and dependence to induction therapy of aflibercept which maintains significant intravitreal VEGF-binding activity for longer time compared to ranibizumab in AMD.

Methods: Medical records of 58 eyes of 54 AMD patients who received initial three monthly intravitreal aflibercept (IVA) induction therapy in our clinic from Feb to Jun 2013 were reviewed. After completion of induction therapy, all eyes were evaluated whether the complete resolution of the intra- or sub-retinal fluid was achieved by spectral-domain optical coherence tomography (SD-OCT) and were classified into well-responded (no further injection needed) or insufficiently-responded group accordingly. If the exudative change in SD-OCT images worsened within three months after completion of induction therapy, the eye was defined as treatment dependent. We thereby studied response and dependence in both naïve and converted from intravitreal ranibizumab (IVR) AMD patients.

Results: Of 58 eyes, 28 eyes were newly treated and 30 eyes were converted from IVR. Of newly treated 28 eyes, 22 eyes (78.6 %) well responded to the induction therapy whereas 6 eyes (21.4%) had insufficient response. In well-responded group, 13 eyes (59.9%) were non-dependent and 9 eyes (40.1%) were dependent. Of 30 eyes converted from IVR, 10 eyes had been well-responded but dependent, and 20 eyes had been insufficiently-responded to IVR. Of the former, 9 eyes (90.0%) were well-responded to IVA, and of the latter, 15 eyes (75.0%) were well-responded and 5 eyes (25.0 %) were insufficiently-responded.

Conclusions: The effect of IVA may be more sufficient than that of IVR in AMD. Seventy-five percent of the eyes which had been insufficiently-responded to IVR well-responded to IVA.

Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor • 561 injection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×